GO
Loading...

Amylin Pharmaceuticals

  • Can Regeneron Continue to Grow?     Monday, 2 Jul 2012 | 2:14 PM ET

    Dr. Leonard Schleifer, Regeneron Pharmaceuticals president & CEO, discusses competition in the pharma sector and upcoming clinical trials. "One of the things that's particularly exciting for a lot of people is our approach to lowering cholesterol," says Schleifer.

  • Bristol Buying Amylin for $7.1 Billion     Monday, 2 Jul 2012 | 2:11 PM ET

    CNBC's Seema Mody discusses the details of the deal between pharma companies Bristol-Myers and Amylin.

  • $7.1 Billion Pharma Deal     Monday, 2 Jul 2012 | 1:11 PM ET

    CNBC's Scott Cohn reports on what the Justice Department calls the biggest health care fraud settlement in U.S. history; and CNBC's Seema Mody reports on the details of Bristol-Myers' plans to buy Amylin.

  • Faber Report: Dish Network Drops AMC     Monday, 2 Jul 2012 | 9:38 AM ET

    CNBC's David Faber reports the Dish Network and AMC contract expired without a new agreement, and a look at the deal between Bristol-Myers and Amylin Pharma.

  • What's Next for Carl Icahn?     Monday, 30 Apr 2012 | 4:14 PM ET

    CNBC's David Faber speaks to activist investor Carl Icahn regarding how much cash he has available to invest and whether Chesapeake Energy is undervalued.

  • Carl Icahn, Icahn Enterprises chairman, discusses his tender offer for CVR Energy, and now holds 69% of the company's shares. Icahn also weighs in on whether Amylin Pharma should be sold, and reveals his thoughts on RIMM, with the Fast Money traders.

  • Amylin CEO Talks Pricing Strategy     Monday, 30 Jan 2012 | 4:45 PM ET

    Daniel Bradbury, Amylin CEO, explains the company's pricing strategy in Europe and how it will catch up with rival Novo Nordisk.

  • Amylin CEO on Exenatide     Tuesday, 8 Nov 2011 | 5:53 PM ET

    Dan Bradbury, Amylin CEO, discusses paying Lilly $250M upfront and $1.2B of future sales for the rights to Exenatide, the once weekly version of diabetes drug, Byetta, that's pending FDA approval.

  • Battling Diabetes Epidemic     Monday, 27 Jun 2011 | 3:27 PM ET

    Daniel Bradbury, Amylin president & CEO, discusses the company's new diabetes drug in Europe. Will it get approval in the US?

Most Popular Video

Friday, 18 Apr 2014 | 11:00 AM ET

Are economic growth expectations too high? CNBC's Jeff Cox explains.

Friday, 18 Apr 2014 | 12:00 PM ET

CNBC's Stephanie Landsman discusses how the luxury rental boom isn't confined to New York City and its boroughs, but that developers are seeing new opportunities in New Jersey.

Thursday, 17 Apr 2014 | 12:00 PM ET

CNBC's Josh Lipton and Allison+Partners Head of Digital Jeremy Rosenberg discuss what Microsoft needs to do to boost Xbox One sales as PS4 sales break the 7 million mark.